全文获取类型
收费全文 | 2588篇 |
免费 | 11篇 |
国内免费 | 1篇 |
专业分类
电工技术 | 3篇 |
化学工业 | 93篇 |
金属工艺 | 4篇 |
机械仪表 | 5篇 |
建筑科学 | 54篇 |
矿业工程 | 3篇 |
能源动力 | 13篇 |
轻工业 | 74篇 |
水利工程 | 5篇 |
石油天然气 | 2篇 |
无线电 | 39篇 |
一般工业技术 | 59篇 |
冶金工业 | 2167篇 |
原子能技术 | 1篇 |
自动化技术 | 78篇 |
出版年
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 12篇 |
2020年 | 3篇 |
2019年 | 7篇 |
2018年 | 14篇 |
2017年 | 9篇 |
2016年 | 6篇 |
2015年 | 11篇 |
2014年 | 11篇 |
2013年 | 22篇 |
2012年 | 19篇 |
2011年 | 15篇 |
2010年 | 18篇 |
2009年 | 16篇 |
2008年 | 19篇 |
2007年 | 24篇 |
2006年 | 30篇 |
2005年 | 16篇 |
2004年 | 21篇 |
2003年 | 16篇 |
2002年 | 14篇 |
2001年 | 7篇 |
2000年 | 8篇 |
1999年 | 78篇 |
1998年 | 634篇 |
1997年 | 365篇 |
1996年 | 269篇 |
1995年 | 160篇 |
1994年 | 127篇 |
1993年 | 131篇 |
1992年 | 29篇 |
1991年 | 40篇 |
1990年 | 30篇 |
1989年 | 49篇 |
1988年 | 48篇 |
1987年 | 39篇 |
1986年 | 28篇 |
1985年 | 40篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 10篇 |
1981年 | 17篇 |
1980年 | 14篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1977年 | 41篇 |
1976年 | 94篇 |
1974年 | 3篇 |
1971年 | 3篇 |
排序方式: 共有2600条查询结果,搜索用时 31 毫秒
171.
Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients
SK Chambers CA Davis JT Chambers PE Schwartz MI Lorber RE Hschumacher 《Canadian Metallurgical Quarterly》1996,2(10):1699-1704
Our objective was to determine the maximum tolerated dose of cyclosporin A (CsA) delivered as a loading dose (LD) and continuous i.v. infusion (CI) in combination with carboplatin in patients with refractory gynecologic cancers. Twenty-nine heavily pretreated patients (25 ovarian epithelial, 2 cervical, and 2 endometrial carcinomas) received 113 cycles of CsA and carboplatin from September 1989 to September 1991. Twenty-four of these 29 carcinomas were strictly defined to be platinum resistant. CsA was administered as a LD escalated from 6 to 10 mg/kg followed by a 24-h CI from 2.5 to 14.5 mg/kg/day. Carboplatin was targeted to an area under the time versus concentration curve (AUC) of 6 mg/ml x min and was not dose escalated. Whole-blood CsA concentrations (fluorescence polarization immunoassay) at the maximum tolerated dose (10 mg/kg LD, 14.5 mg/kg/day CI) ranged from 2.4 to 3.0 microgram/ml over 12 h. Estimated median carboplatin AUC, based on calculated carboplatin clearance, was 7.9 mg/ml x min. The dose-limiting toxicity of the combination of CsA and carboplatin was grade 4 thrombocytopenia. Grade 3 or 4 thrombocytopenia occurred in 35% of the patients, which could be explained by the effects of carboplatin (AUC of 6 mg/ml x min) alone. Overall, neutropenia occurred in 24% of the patients and anemia in 17% of the patients. Grade 3 or 4 nausea or vomiting was noted in 10 and 14% of the patients, respectively. Grade 3 hypertension during CsA administration occurred in 14% of the patients. No grade 3 or 4 nephrotoxicity was seen in this trial. Three objective responses were noted: one complete response (11 months) and one partial response (5 months), both in potentially platinum-sensitive patients with platinum-free intervals of only 9 months each. One platinum-resistant patient had a partial response for 21 months. Five additional patients experienced >75% reduction of CA-125 or a return to a normal CA-125 titer. We concluded that whole-blood CsA concentrations of >3.0 microgram/ml (as seen when CsA is used as a modulator of multidrug resistance) were not achievable in this combination with carboplatin in this population of heavily pretreated gynecologic cancer patients. However, because CsA is used in this trial as a chemosensitizer in platinum-sensitive tumors and as a chemomodulator of platinum resistance, we targeted a CsA concentration of >1.0 microgram/ml, which was achieved. The CsA dose recommended for a Phase II trial of this combination is 10 mg/kg LD and 11.6 mg/kg/day CI, which results in blood CsA concentrations ranging from 1.2 to 1.3 microgram/ml over 12 h. Responses in this population of refractory gynecologic cancer patients are unusual, and these encouraging results form the basis for a Phase II trial of this combination. 相似文献
172.
173.
174.
Louise C W Wiggers Frans J Oort Ron J G Peters Dink A Legemate Hanneke C J M de Haes Ellen M A Smets 《Nicotine & tobacco research》2006,8(4):581-589
The benefits of smoking cessation on patients' medical conditions are well documented. Cardiovascular patients who quit smoking significantly reduce their risk of a new event compared with those who continue smoking. Several studies have found that smoking is related to poor quality of life (QoL). In cardiovascular patients, however, less attention has been given to the effect of smoking cessation on patients' QoL. The present study examined the extent to which smoking cessation leads to changes in QoL in these patients within the first year of follow-up. Data were collected in the context of a randomized clinical trial. Smoking outpatients (N = 346) with atherosclerotic disease were included and received medical treatment. They were randomized to receive either nicotine replacement therapy (NRT) or NRT plus a behavioral intervention meant to promote smoking cessation. At baseline, sociodemographic and clinical characteristics were established. Generic and disease-specific QoL as well as smoking status were assessed at baseline and with three follow-up measurements. Multilevel modeling showed that generic and disease-specific QoL in atherosclerotic patients improved significantly within the first year of follow-up. No main differences were found between quitters and smokers in terms of improvement in QoL. In fact, some subgroups reported a poorer QoL after smoking cessation: More highly educated patients reported lower general QoL (p < .05), and patients suffering from coronary artery disease who had a low level of education (p < .01) and patients suffering from peripheral arterial disease who had low nicotine dependency (p < .01) reported lower disease-specific QoL. Atherosclerotic patients' QoL improved significantly but was not enhanced by smoking cessation activities. 相似文献
175.
176.
177.
178.
Three consecutive cases of pediatric myelodysplastic syndrome (MDS) diagnosed over a three-year period in Queen Mary Hospital, Hong Kong, were described. Depending on the classification system used, they comprised two cases of chronic myelomonocytic leukemia (CMMoL) of which one can be reclassified as juvenile chronic myeloid leukemia (JCML) and one cases of refractory anemia with excess of blasts (RAEB) or an alternative diagnosis of atypical CML. Cytogenetic abnormalities were detected in all of them on examination of bone marrow cells. Of the two CMMoL, one had monosomy 21, whereas the other had hypodiploidy. The patient with RAEB had a complex karyotype of 46,X,del(X)(q24),t(1;7) (p22;q32),add(15)(q26)(8). The balanced translocation (1;7) seen in this patient was exceedingly rare and, to the best of our knowledge, was reported only twice in the literature. The karyotypic abnormalities that we saw in our patients were not well recognized in pediatric MDS. This report emphasizes the importance of cytogenetic study in children suspected of suffering from MDS, which remains a rare disorder of childhood, and a need to rationalize current classification schemes. 相似文献
179.
In radioimmunotherapy, the long circulation times of antibody radioconjugates correlate with high relative radiation doses to nontumor tissues. Tumor/normal tissue ratios can be significantly improved by using targeting molecules with shorter circulation times. IFabs are multimers of VH-CH1-linker-VK-CK monomers. The lack of the Fc region in IFabs should lead to circulation times that are shorter than those of IgG molecules. The monomers assemble into disulfide-bond-stabilized multimers, 90% of which are 100 kDa dimers (IFab2). IFab2s should not be rapidly eliminated through kidney filtration because their molecular weight is above the threshold for renal passage. We report the first experimental in vivo tests for 125I-IFab radioconjugates derived from a humanized version of the anti-breast mucin monoclonal antibody BrE-3. Biodistributions are reported for athymic nude mice carrying human mammary tumor MX-1 xenografts. The T1/2 beta's for the different tissues ranged from 13.3 h for blood to 19.9 h for tumor. Therefore, IFab radioconjugates cleared the body with a rate comparable to that of F(ab')2 fragments. Except for stomach, tumor/nontumor dose ratios were significantly better for IFabs than for the parent antibody (BrE-3)4 days after injection. 相似文献
180.
A Miller JP Salenius BA Sacks SK Gupta GM Shoukimas 《Canadian Metallurgical Quarterly》1997,26(4):715-720
Depressed geriatric patients show substantial intersubject variability in cognitive performance, which complicates attempts to evaluate the cognitive effects of depression and of antidepressant therapy. This variability may reflect the multiple medications older patients take, many of which have anticholinergic effects. This study examined whether serum anticholinergicity (SA) explained some of the variability in depressed geriatric patients' memory performance. Before starting antidepressant treatment, 36 elderly depressed subjects were given a verbal learning test. At the same time, a blood sample was taken and analyzed by radioreceptor binding assay to determine their SA level. Nineteen of the subjects had detectable levels (mean = 0.28 pmole atropine equivalent). Subjects with an SA of zero showed significantly better delayed recall than did those with a positive SA level. Thus, even very low SA may produce subtle decrements in memory performance, an area of cognition known to be highly sensitive to anticholinergic effects. 相似文献